PULM
Pulmatrix Inc
NASDAQ · Pharmaceuticals
$2.48
-0.01 (-0.40%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 1.36M | 1.27M | 1.06M |
| Net Income | 333.6K | 357.5K | 314.0K |
| EPS | — | — | — |
| Profit Margin | 24.6% | 28.2% | 29.6% |
| Rev Growth | +18.9% | -7.0% | +4.1% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 4.39M | 3.67M | 4.18M |
| Total Equity | 5.61M | 5.19M | 5.68M |
| D/E Ratio | 0.78 | 0.71 | 0.74 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 634.9K | 531.9K | 486.7K |
| Free Cash Flow | 335.1K | 275.9K | 324.6K |